| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/23/2014 | WO2014014270A1 Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase |
| 01/23/2014 | WO2014013903A1 Liquid composition containing taxane-based active ingredient, process for producing same, and liquid medicinal preparation |
| 01/23/2014 | WO2014013231A1 Materials and methods for treating pten mutated or deficient cancer |
| 01/23/2014 | WO2014013060A1 Osteopontin peptide fragments for use in suppression or prevention of tumor growth |
| 01/23/2014 | WO2014013032A1 Hip/pap protein and derivatives thereof for use in treating cancer |
| 01/23/2014 | WO2014013019A1 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
| 01/23/2014 | WO2014012997A1 Composition for therapeutic use, including an organic lipid phase and a rare- earth radioisotope complex |
| 01/23/2014 | WO2014012942A1 Use of vegfr-3 inhibitors for treating hepatocellular carcinoma |
| 01/23/2014 | WO2014012889A1 Anti-angiogenic compounds |
| 01/23/2014 | WO2014012511A1 N-(3-heteroarylaryl)-4-arylarylcarboxamtdes and analogs as hedgehog pathway inhibitors and use thereof |
| 01/23/2014 | WO2014012495A1 Chiral α-methylene-β-lactam compound and preparation method and application thereof |
| 01/23/2014 | WO2014012480A1 Polymorphs of deuterated omega-diphenylurea or salts thereof |
| 01/23/2014 | WO2014012479A1 Compounds for targeted immunotherapy |
| 01/23/2014 | WO2014012147A1 Method of diagnosis and treatment |
| 01/23/2014 | WO2013188763A9 Compositions for treating cancer and methods for making the same |
| 01/23/2014 | WO2013095736A3 Gold-in-silicon nanoassembly for thermal therapy and methods of use |
| 01/23/2014 | US20140024695 Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
| 01/23/2014 | CA2875486A1 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
| 01/22/2014 | EP2687541A1 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| 01/22/2014 | EP2687540A1 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| 01/22/2014 | EP2687537A1 Polypeptide drug against hepatitis b virus x protein |
| 01/22/2014 | EP2687531A1 Tetrahydrocarboline derivative |
| 01/22/2014 | EP2687516A1 Inhibitors of C-FMS Kinase |
| 01/22/2014 | EP2687509A2 Dicarboxyimides derivatives for use in the treatment of cancer |
| 01/22/2014 | EP2687231A1 Composition for treatment and diagnosis of pancreatic cancer |
| 01/22/2014 | EP2687225A1 HIP/PAP protein and derivatives thereof for use in treating cancer |
| 01/22/2014 | EP2687218A1 Pharmaceutical composition and manufacturing method therefor |
| 01/22/2014 | EP2687216A2 Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor |
| 01/22/2014 | EP2687211A1 Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis |
| 01/22/2014 | EP2687209A1 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| 01/22/2014 | EP2687204A1 Vector for pulmonary delivery, inducing agent, and uses |
| 01/22/2014 | EP2687203A1 Emulsified composition for dilution and cancer vaccine composition |
| 01/22/2014 | EP2686342A2 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use |
| 01/22/2014 | EP2686336A1 N-carboxyalkyl-auristatins and use thereof |
| 01/22/2014 | EP2686319A1 Imidazo pyrazines |
| 01/22/2014 | EP2686318A1 Pyrrolopyridineamino derivatives as mps1 inhibitors |
| 01/22/2014 | EP2686317A2 Raf kinase inhibitors |
| 01/22/2014 | EP2686314A1 6,5-heterocyclic propargylic alcohol compounds and uses therefor |
| 01/22/2014 | EP2686298A1 Substituted diphenyl derivatives |
| 01/22/2014 | EP2686008A1 Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence |
| 01/22/2014 | EP2686001A1 Uses of modified elr-cxc chemokine g31p to treat cancer |
| 01/22/2014 | EP2685995A1 Yeast-brachyury immunotherapeutic compositions |
| 01/22/2014 | EP2685990A1 Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| 01/22/2014 | EP2685989A1 Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer |
| 01/22/2014 | EP2685988A2 Methods of treating breast cancer with anthracycline therapy |
| 01/22/2014 | EP2685985A1 Methods for treating leukemia and disorders mediated by cbf and runx1 proteins |
| 01/22/2014 | EP2685980A1 Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| 01/22/2014 | EP2685823A1 Treatment of cancer |
| 01/22/2014 | EP1407047B1 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 01/22/2014 | CN103534593A The use anti-CXCL16 and anti- CXCR6 antibodies for the treatment or detecting cancer |
| 01/22/2014 | CN103534272A Antibody specifically recognising transferrin receptor |
| 01/22/2014 | CN103534258A 酪氨酸激酶抑制剂 Tyrosine kinase inhibitors |
| 01/22/2014 | CN103534257A Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
| 01/22/2014 | CN103534254A Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent |
| 01/22/2014 | CN103534241A Fak抑制剂 Fak inhibitors |
| 01/22/2014 | CN103534240A Selective FAK inhibitors |
| 01/22/2014 | CN103534239A Substituted indazole derivatives active as kinase inhibitors |
| 01/22/2014 | CN103533942A Method for administration of a gamma secretase inhibitor |
| 01/22/2014 | CN103533941A Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
| 01/22/2014 | CN103533940A Method for treatment of advanced solid tumors |
| 01/22/2014 | CN103533939A Multiple myeloma treatment |
| 01/22/2014 | CN103533936A Liposome containing pyrroloquinoline quinone and sugar |
| 01/22/2014 | CN103525941A Application of CTHRC1 genes in preparation of drugs for detecting/treating cervical cancer |
| 01/22/2014 | CN103525905A Application of miRNA in preparation of medicaments and diagnostic reagents for treating primary aldosteronism adenoid tumors |
| 01/22/2014 | CN103525900A Nucleic acid suppression molecule for suppressing expression of brain eIF6 gene and screening method and application thereof |
| 01/22/2014 | CN103525846A Coding gene sequence and amino acid sequence of arenicola cristata protease with antitumor activity |
| 01/22/2014 | CN103525845A CDNA sequence and amino acid sequence of lugworm protease with antineoplastic activity |
| 01/22/2014 | CN103525657A Crocodile blood health wine and preparation method |
| 01/22/2014 | CN103524639A Synthesis method and application of chitosan oligosaccharide/indometacin graft |
| 01/22/2014 | CN103524628A Recombinant ganoderma lucidum immunoregulatory protein, human serum albumin fusion protein, and preparation method and application thereof |
| 01/22/2014 | CN103524627A Double-target-spot fusion protein capable of enhancing TRAIL antitumor activity |
| 01/22/2014 | CN103524626A Recombinant double-target protein medicine and application thereof |
| 01/22/2014 | CN103524621A Anti-human CD20 chimeric monoclonal antibody |
| 01/22/2014 | CN103524620A Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment |
| 01/22/2014 | CN103524619A Antibodies directed to avss6 and uses thereof |
| 01/22/2014 | CN103524599A Cyclopeptide luteinizing hormone releasing hormone (LHRH) antagonist derivatives and pharmaceutical use thereof |
| 01/22/2014 | CN103524598A Cyclic peptide compound and preparation method thereof as well as medicinal composition and application thereof |
| 01/22/2014 | CN103524584A Synthetic method of azacitidine |
| 01/22/2014 | CN103524567A Anti human osteosarcoma zinc-containing heteropoly compound and synthetic method thereof |
| 01/22/2014 | CN103524564A Synthesis method and application of platinum (II) complex of 6-amino oxoisoaporphine |
| 01/22/2014 | CN103524556A Diacerhein aminophosphonate derivatives, and synthetic method and applications thereof |
| 01/22/2014 | CN103524555A Rhein aminophosphonate derivatives, and synthetic method and applications thereof |
| 01/22/2014 | CN103524535A Amido thiazole-pyridine heterocycle compound with activity of hedgehog path antagonist |
| 01/22/2014 | CN103524524A New compound in fructus schizandrae as well as preparation and application method of new compound |
| 01/22/2014 | CN103524519A Camptothecin prodrug monomer and polymeric prodrug amphipathic molecules thereof as well as preparation method and application of camptothecin prodrug monomer and polymeric prodrug amphipathic molecules |
| 01/22/2014 | CN103524513A Two-type 3-acyl-2, 4-pyrrolidine-diketone compound and synthesis method thereof |
| 01/22/2014 | CN103524512A Indole spiro pyrrolo [1,2-c] imidazole compound, and preparation method and application thereof |
| 01/22/2014 | CN103524509A Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| 01/22/2014 | CN103524506A Preparation method and application of radioiodine labeled biomolecules |
| 01/22/2014 | CN103524463A Method for rapidly preparing great burdock achene aglycone from great burdock achene |
| 01/22/2014 | CN103524442A Pyrimidine compound, triazine compound and application thereof as medicine |
| 01/22/2014 | CN103524436A 1-[(3-alkoxy-6-substituted-quinoxalin-2-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives |
| 01/22/2014 | CN103524421A Novel naphthoyl urea derivate and medical application thereof |
| 01/22/2014 | CN103524412A Isoquinolone derivative and synthetic method thereof |
| 01/22/2014 | CN103524409A Quinoline compound as well as preparation method and application thereof |
| 01/22/2014 | CN103524397A 3-sulfimidyl indole compound and preparation method thereof |
| 01/22/2014 | CN103524393A Azetidine-3-sulfanilamide derivative and synthetic method thereof |
| 01/22/2014 | CN103524392A Azetidines as mek inhibitors for the treatment of proliferative diseases |
| 01/22/2014 | CN103524372A Novel histone deacetylase inhibitor |
| 01/22/2014 | CN103524349A CA-4 carbonate derivatives, and preparation method, pharmaceutical composition and medical application thereof |